Spire Wealth Management’s Accelerate Diagnostics AXDX Stock Holding History
Bought
Maintained
Sold
Other funds holding AXDX
OIM
BC
CC
GAM
Spire Wealth Management's AXDX Position: Q4 2021 in Review
Spire Wealth Management sold out of Accelerate Diagnostics (AXDX) in Q4 2021, closing a stake of 600 shares — an estimated $35K sold.
Spire Wealth Management first reported a position in AXDX in Q1 2021 and held it in 3 quarters. The position peaked at $50K in Q1 2021. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2021.
- Spire Wealth Management reported no remaining Accelerate Diagnostics position as of Q4 2021 after selling out during the quarter.
- Spire Wealth Management sold 600 Accelerate Diagnostics shares in Q4 2021, an estimated $35K.
- Spire Wealth Management first reported a position in Accelerate Diagnostics in Q1 2021 and held it in 3 quarters.
- Spire Wealth Management's Accelerate Diagnostics position peaked at $50K in Q1 2021.
- 107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2021.
Based on Spire Wealth Management's 13F filing for Q4 2021, filed 14 Jan 2022.